Unknown

Dataset Information

0

Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation.


ABSTRACT: Afatinib is a second-generation of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor and has shown a significant clinical benefit in non-small cell lung cancer (NSCLC) patients with EGFR-activating mutations. However, the potential therapeutic effects of afatinib combining with other modalities, including ionizing radiation (IR), are not well understood. In this study, we developed a gefitinib-resistant cell subline (PC-9-GR) with a secondary EGFR mutation (T790M) from NSCLC PC-9 cells after chronic exposures to increasing doses of gefitinib. The presence of afatinib significantly increases the cell killing effect of radiation in PC-9-GR cells harboring acquired T790M, but not in H1975 cells with de novo T790M or in H460 cells that express wild-type EGFR. In PC-9-GR cells, afatinib remarkable blocks baseline of EGFR and ERK phosphorylations, and causes delay of IR-induced AKT phosphorylation. Afatinib treatment also leads to increased apoptosis and suppressed DNA damage repair in irradiated PC-9-GR cells, and enhanced tumor growth inhibition when combined with IR in PC-9-GR xenografts. Our findings suggest a potential therapeutic impact of afatinib as a radiation sensitizer in lung cancer cells harboring acquired T790M mutation, providing a rationale for a clinical trial with combination of afatinib and radiation in NSCLCs with EGFR T790M mutation.

SUBMITTER: Zhang S 

PROVIDER: S-EPMC4467405 | biostudies-literature | 2015 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation.

Zhang Shirong S   Zheng Xiaoliang X   Huang Haixiu H   Wu Kan K   Wang Bing B   Chen Xufeng X   Ma Shenglin S  

Oncotarget 20150301 8


Afatinib is a second-generation of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor and has shown a significant clinical benefit in non-small cell lung cancer (NSCLC) patients with EGFR-activating mutations. However, the potential therapeutic effects of afatinib combining with other modalities, including ionizing radiation (IR), are not well understood. In this study, we developed a gefitinib-resistant cell subline (PC-9-GR) with a secondary EGFR mutation (T790M) from NSCLC PC-9  ...[more]

Similar Datasets

| S-EPMC4771182 | biostudies-literature
| S-EPMC7327692 | biostudies-literature
| S-EPMC5620242 | biostudies-literature
| S-EPMC4830020 | biostudies-literature
| S-EPMC4977654 | biostudies-other
| S-EPMC6938756 | biostudies-literature
| S-EPMC7577810 | biostudies-literature
| S-EPMC8176237 | biostudies-literature
| S-EPMC10579823 | biostudies-literature
| S-EPMC4585860 | biostudies-other